Company intelligence / Profile preview

MEDICAL IP

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

MEDICAL IP has developed FDA-cleared solutions for whole-body composition analysis using advanced AI-driven medical image segmentation. Their technologies have been clinically validated in areas such as neurosurgery (3D brain disease models) and kidney cancer surgery planning with successful published results. The company’s DeepCatch X product enhances diagnostic accuracy in chest X-rays through AI visualization. They have also received regulatory clearances including FDA 510(k) for ‘DeepCatch’ and MFDS approval for ‘TiSepX Lung Volumetry’.

Therapeutic areas: Metabolic DisordersOncologyNeurology
Modalities: DeviceSoftware (AI-powered medical imaging)3D printingAR/VR-based simulation
Industry: Medical Imaging

Partnerships

NVIDIA Inception Premier PartnershipAmazon Web Services Letter of Support

Beyond the preview

Go deeper on MEDICAL IP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEDICAL IP.

Explore the full profile